2016 FORUM PRESENTERS (Alphabetical)

Julia Allen, MCP, RCC; Panel: “A New Medical Model: Holistic Medicine and Psychedelic Psychotherapy

Meaghan Buisson, 47-time Canadian national champion and current world record holder in the sport of inline speed skating; one of six Canadian participants in the Phase II clinical trial for MDMA-assisted psychotherapy for treatment-resistant PTSD. Presentation: “MDMA-Assisted Psychotherapy: A Personal Journey

Devon Christie, MD; Certified Functional Medicine Practitioner, with the US-based Institute for Functional Medicine (IFM). Presentation: “An Invitation to Wholeness: Psychedelic & the Future of Medicine;” Panels: “A New Medical Model: Holistic Medicine and Psychedelic Psychotherapy;” “Tying Your Shoes in Hyperspace: Integrating the Psychedelic Experience.”

Sasha Cuff, RTC(c)  Panels: “A New Medical Model: Holistic Medicine and Psychedelic Psychotherapy;” “Tying Your Shoes in Hyperspace: Integrating the Psychedelic Experience.”

Rick Doblin, Ph.D., founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). Keynote address: “Mainstreaming Psychedelics: Six Decades of Cultural Evolution from 1966 to 2026” Panel: “MDMA: The Promise and Challenge for  New Paradigm of Healing

Donna Dryer, MD, FRCPC, is a transpersonal psychiatrist in private practice on the coast islands of British Columbia; assisted with MAPS sponsored research study of MDMA for people with treatment- resistant Post Traumatic Stress Disorder in Vancouver. Panels: “MDMA: The Promise and Challenge for  New Paradigm of Healing;” “Harvard or Hogwarts? – Training the Psychedelic Psychotherapists

Frank Echenhofer, PhD; Panels: “The Mystical Experience in Psychedelic Work;” “Tying Your Shoes in Hyperspace: Integrating the Psychedelic Experience.”

Yalila Espinoza, PhD, integrative health advisor; Panel: “Tying Your Shoes in Hyperspace: Integrating the Psychedelic Experience.”

Carolyn Green, PhD, certified Grof facilitator; Panel: “Holotropic (TM) Breathwork

Mark Haden, MSW; Chair, MAPS Canada; Adjunct Professor at the University of British Columbia School of Population and Public Health; Presentation: “A Post-Prohibition Model for the Regulation of Psychedelics

James Jesso, author of Decomposing The Shadow and The True Light Of Darkness; Presentation: “Potential Mechanisms Behind the Treatment of Chronic Depression with Psilocybin

Adèle Lafrance, PhD, C. Psych; Psychologist and Associate Professor at Laurentian University in Sudbury, Ontario; Presentation: “Feeding the Soul with Ayahuasca-assisted Therapy: A Promising Treatment of the Healing of Eating Disorders;” “The Mystical Experience in Psychedelic Work

Philippe Lucas, Vice President of Patient Advocacy at Tilray, a federally authorized medical cannabis production, research and distribution company based in Nanaimo, BC; Presentation: “Medical Cannabis & Mental Health Research Under the MMPR

Sarah Mattson; Presentation: “A Post-Prohibition Model for the Regulation of Psychedelics

Trevor Millar, owner of Liberty Root Therapy; Presentation: “Psychedelic Entrepreneurship

Marcela Ot’alora, MA, LPC, co-therapist in the first government approved MDMA-assisted psychotherapy study in Madrid Spain; Principal Investigator of the Phase II MDMA-assisted psychotherapy study in Boulder, Colorado. Presentation: “Relieving Symptoms of PTSD with MDMA;” Panel: “MDMA: The Promise and Challenge for  New Paradigm of Healing

Ingrid Pacey, MD, psychiatrist; lead investigator of MDMA/PTSD study to Vancouver completed in 2017. Panels: “MDMA: The Promise and Challenge for  New Paradigm of Healing;” “Holotropic (TM) Breathwork

Dawn Rabey, PhD, CCC, RCC; transpersonal psychotherapist in Victoria, BC. Panel: “Tying Your Shoes in Hyperspace: Integrating the Psychedelic Experience.”

William A. (Bill) Richards, PhD; psychologist in the Psychiatry Department of the Johns Hopkins University School of Medicine, where he and his colleagues have pursued psychedelic research during the past 16 years. Presentation: “Psilocybin Studies and Implications for Cancer Patients and End of Life Issues;” Panel: “The Mystical Experience in Psychedelic Work

Hayden Rubensohn, MD; Panel: “MDMA: The Promise and Challenge for  New Paradigm of Healing

Bruce Tobin, PhD, RCC; Panel: “The Road Forward to Legal Psychedelic Psychotherapy: the Moving Forward Project;” “Holotropic (TM) Breathwork

Zach Walsh, PhD; Presentation: “Psychedelic Therapy and Third-wave Behaviorism: New Directions for the Prevention of Interpersonal Violence

Richard Yensen, PhD; co-principal investigator for the MAPS sponsored PTSD & MDMA phase 2 psychotherapy study completed in 2017 in Vancouver. Panels: “MDMA: The Promise and Challenge for  New Paradigm of Healing;” “Harvard or Hogwarts? – Training the Psychedelic Psychotherapists

2015 FORUM PRESENTERS (Alphabetical)

Donna Dryer, MD, FRCPC, is a transpersonal psychiatrist in private practice on the coast islands of British Columbia; assisted with MAPS sponsored research study of MDMA for people with treatment- resistant Post Traumatic Stress Disorder in Vancouver. Panels: “Panels: “Engaging in Psychedelic Training & Research Partnerships;” “Monetizing a Mystery;” “Integrating Cosmos and Psyche: Facilitating the Psycho-Spiritual Bridge with Clients

Frank Echenhofer, PhD; Panels: “The Mystical Experience in Psychedelic Work;” “Tying Your Shoes in Hyperspace: Integrating the Psychedelic Experience.”

Yalila Espinoza, PhD, integrative health advisor; Panel: “Ayahuasca Therapists: Shamans or Shrinks;” “Integrating Cosmos and Psyche: Facilitating the Psycho-Spiritual Bridge with Clients

Andrew Feldmar, MA, psychotherapist; Presentation:Therapeutic Use of Psychedelics: Overview & Personal Journey;” “Integrating Cosmos and Psyche: Facilitating the Psycho-Spiritual Bridge with Clients

Mark Haden, MSW; Chair, MAPS Canada; Adjunct Professor at the University of British Columbia School of Population and Public Health; Presentation: “A Realistic Approach to Drug Education: How to Talk to Youth about Drugs;” Panel: “Legal and Ethics: Guidelines, Safety, and Practical Tools for Therapists”

Philippe Lucas, Vice President of Patient Advocacy at Tilray, a federally authorized medical cannabis production, research and distribution company based in Nanaimo, BC; Presentation: “Medical Cannabis & Mental Health Research Under the MMPR

 

Gabor Maté, MD; Keynote address: “Through Past and Future into the Present: What Psychedelics can teach us;” Panel: “Iboga and the Treatment of Addictions

Trevor Millar, owner of Liberty Root Therapy; Panels: “Iboga and the Treatment of Addictions;” “Legal and Ethics: Guidelines, Safety, and Practical Tools for Therapists”

Ingrid Pacey, MD, psychiatrist; lead investigator of MDMA/PTSD study to Vancouver completed in 2017. Presentation: “Holotropic Breathwork, Psychedelics and PTSD

Kevin Parker, MA, RCC; Panel: “Monetizing a Mystery

Hayden Rubensohn, MD; Panel: “Engaging in Psychedelic Training & Research Partnerships

Soheil Samimi; Panels: “Ayahuasca Therapists: Shamans or Shrinks;” “Legal and Ethics: Guidelines, Safety, and Practical Tools for Therapists”

Bruce Tobin, PhD, RCC; Panel: “Legal and Ethics: Guidelines, Safety, and Practical Tools for Therapists

Kirk Tousaw, Barrister and advocate, Tousaw Law Corporation; Panel: “Legal and Ethics: Guidelines, Safety, and Practical Tools for Therapists”

Zach Walsh, PhD; Presentation: “Cannabis and the Treatment of PTSD

Richard Yensen, PhD; co-principal investigator for the MAPS sponsored PTSD & MDMA phase 2 psychotherapy study completed in 2017 in Vancouver. Panels: “Engaging in Psychedelic Training & Research Partnerships;” “Monetizing a Mystery.”